GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Schrodinger Inc (STU:43Z) » Definitions » Total Liabilities

Schrodinger (STU:43Z) Total Liabilities : €383.7 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Schrodinger Total Liabilities?

Schrodinger's Total Liabilities for the quarter that ended in Dec. 2024 was €383.7 Mil.

Schrodinger's quarterly Total Liabilities declined from Jun. 2024 (€199.17 Mil) to Sep. 2024 (€198.10 Mil) but then increased from Sep. 2024 (€198.10 Mil) to Dec. 2024 (€383.70 Mil).

Schrodinger's annual Total Liabilities increased from Dec. 2022 (€227.20 Mil) to Dec. 2023 (€233.28 Mil) and increased from Dec. 2023 (€233.28 Mil) to Dec. 2024 (€383.70 Mil).


Schrodinger Total Liabilities Historical Data

The historical data trend for Schrodinger's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schrodinger Total Liabilities Chart

Schrodinger Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial 100.49 176.47 227.20 233.28 383.70

Schrodinger Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.28 206.13 199.17 198.10 383.70

Schrodinger Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Schrodinger's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=183.118+(96.526+0.14000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+103.917+0+0)
=383.7

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=786.181-402.48
=383.7

Schrodinger's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=183.118+(96.526+0.14000000000003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+103.917+0+0)
=383.7

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=786.181-402.48
=383.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schrodinger Total Liabilities Related Terms

Thank you for viewing the detailed overview of Schrodinger's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Schrodinger Business Description

Traded in Other Exchanges
Address
1540 Broadway, 24th Floor, New York, NY, USA, 10036
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Schrodinger Headlines

No Headlines